According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...
GlobalData on MSN3d
Pfizer reports positive data from prostate cancer combination therapy trialIn the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...
Ahmedabad: Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received ...
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...
The objectives of this symposium were to improve attendees’ knowledge on ADT, including the different therapeutic options ...
FibroGen Inc (FGEN) reports significant revenue increases and strategic pivots amid challenges in clinical trials and market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback